Additional file 1: Figure S1. of High-dose interleukin2 â a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome

Chow, S.; Galvis, V.; Pillai, M.; Leach, R.; Keene, E.; Spencer-Shaw, A.; Shablak, A.; Shanks, J.; Liptrot, T.; Thistlethwaite, F.; Hawkins, R.

doi:10.6084/m9.figshare.c.3611852_D1.v1

40425_2016_174_MOESM1_ESM.docx (80.56 kB)

Additional file 1: Figure S1. of High-dose interleukin2 â a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome

journal contribution

posted on 2016-10-18, 05:00 authored by S. Chow, V. Galvis, M. Pillai, R. Leach, E. Keene, A. Spencer-Shaw, A. Shablak, J. Shanks, T. Liptrot, F. Thistlethwaite, R. Hawkins

(a) Survival curve showing overall survival by response to HD IL2 and (b) Percentage of survival by response at 1, 3 and 5-years. (DOCX 80 kb)

History

Usage metrics

Keywords

High dose interleukin2 Cytokine therapy Metastatic renal cell carcinoma Pathology selection criteria

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC